1928ZT-2 is under clinical development by Wellington Zhaotai Therapies and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 1928ZT-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
1928zT-2 is under development for the treatment of relapsed and refractory CD19 positive B-cell acute leukemia and lymphoma. It is administered as an infusion. The therapy comprises of autologous T cells genetically modified by lentiviral transduction to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.
For a complete picture of 1928ZT-2’s drug-specific PTSR and LoA scores, buy the report here.